Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Nanoscale ; 11(39): 18426-18435, 2019 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-31576881

RESUMO

This work explored the application of matrix metalloproteinase 2-targeted superparamagnetic nanoprobes for magnetic resonance imaging (MRI), near infrared (NIR) fluorescence imaging and photodynamic therapy of tumors. PEG, PAMAM (G5) and matrix metalloproteinase 2 (MMP2) were attached to the surface of carboxylated Fe3O4 nanoparticles (NPs) using a chemical coupling method and then finally loaded with the photosensitizer chlorin e6 (Ce6). In vitro and in vivo experiments demonstrated that the Fe3O4-PEG-G5-MMP2@Ce6 nanoprobes exhibited excellent stability, precise tumor targeting and biocompatibility. Furthermore, the fluorescence properties of Fe3O4-PEG-G5-MMP2@Ce6 nanoprobes were analogous to Ce6 and could be employed for fluorescence imaging. Meanwhile, the Fe3O4-PEG-G5-MMP2@Ce6 nanoprobes have also been shown to be effective as contrast agents for T2-weighted MRI. The target molecule MMP2 enhanced the tumor targeting ability of Fe3O4-PEG-G5-MMP2@Ce6 nanoprobes. Additionally, the Fe3O4-PEG-G5-MMP2@Ce6 nanoprobes significantly inhibited tumor growth compared with PBS and free Ce6. This work will inspire greater enthusiasm for the construction of multifunctional magnetic nanoplatforms for biomedical applications.


Assuntos
Nanopartículas de Magnetita , Neoplasias Experimentais , Imagem Óptica , Fotoquimioterapia , Fármacos Fotossensibilizantes , Animais , Linhagem Celular Tumoral , Clorofilídeos , Feminino , Humanos , Nanopartículas de Magnetita/química , Nanopartículas de Magnetita/uso terapêutico , Metaloproteinase 2 da Matriz/química , Metaloproteinase 2 da Matriz/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Neoplasias Experimentais/diagnóstico por imagem , Neoplasias Experimentais/tratamento farmacológico , Fármacos Fotossensibilizantes/química , Fármacos Fotossensibilizantes/farmacologia , Porfirinas/química , Porfirinas/uso terapêutico , Ensaios Antitumorais Modelo de Xenoenxerto
2.
ACS Appl Mater Interfaces ; 8(5): 3438-45, 2016 Feb 10.
Artigo em Inglês | MEDLINE | ID: mdl-26759926

RESUMO

Fibrotic stroma, a critical character of pancreatic tumor microenvironment, provides a critical barrier against the penetration and efficacy of various antitumor drugs. Therefore, new strategies are urgently needed to alleviate the fibrotic mass and increase the drug perfusion within pancreatic cancer tissue. In our current work, we developed a ß-cyclodextrin (ß-CD) modified matrix metalloproteinase-2 (MMP-2) responsive liposome, integrating antifibrosis and chemotherapeutic drugs for regulation of pancreatic stellate cells (PSCs), a key source of the fibrosis, and targeted delivery of cytotoxic drugs for pancreatic cancer therapy. These liposomes disassembed into two functional parts upon MMP-2 cleavage at the tumor site. One part was constituted by the ß-CDs and the antifibrosis drug pirfenidone, which was kept in the stroma and inhibited the expression of collagen I and TGF-ß in PSCs, down-regulating the fibrosis and decreasing the stromal barrier. The other segment, the RGD peptide-modified-liposome loading the chemotherapeutic drug gemcitabine, targeted and killed pancreatic tumor cells. This integrated nanomedicine, showing an increased drug perfusion without any overt side effects, may provide a potential strategy for improvement of the pancreatic cancer therapy.


Assuntos
Sistemas de Liberação de Medicamentos , Fibrose/tratamento farmacológico , Metaloproteinase 2 da Matriz/química , Neoplasias Pancreáticas/tratamento farmacológico , Liberação Controlada de Fármacos , Fibrose/patologia , Humanos , Lipossomos/química , Lipossomos/uso terapêutico , Metaloproteinase 2 da Matriz/uso terapêutico , Nanomedicina , Neoplasias Pancreáticas/patologia , Células Estreladas do Pâncreas/efeitos dos fármacos , Células Estreladas do Pâncreas/patologia , Células Estromais/efeitos dos fármacos , Células Estromais/patologia , Microambiente Tumoral/efeitos dos fármacos , beta-Ciclodextrinas/química , beta-Ciclodextrinas/uso terapêutico
3.
Antimicrob Agents Chemother ; 50(10): 3277-82, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17005805

RESUMO

Chlamydophila pneumoniae is a pathogen that is involved in acute and chronic respiratory infections and that is associated with asthma and coronary artery diseases. In this study, we evaluated the effects of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, against experimental infections caused by C. pneumoniae. Moreover, we investigated the relationships between C. pneumoniae and alpha(v)beta(3) integrin functions in order to explain the possible mechanism of action of PEX both in vitro and in vivo. For the in vitro experiments, HeLa cells were infected with C. pneumoniae and treated with either PEX or azithromycin. The results obtained with PEX were not significantly different (P > 0.05) from those achieved with azithromycin. Similar results were also obtained in a lung infection model. Male C57BL/J6 mice inoculated intranasally with 10(6) inclusion-forming units of C. pneumoniae were treated with either PEX or azithromycin plus rifampin. Infected mice treated with PEX showed a marked decrease in C. pneumoniae counts versus those for the controls; this finding did not differ significantly (P > 0.05) from the results observed for the antibiotic-treated group. Integrin alpha(v)beta(3) plays an important role in C. pneumoniae infection. Blockage of integrin activation led to a significant inhibition of C. pneumoniae infection in HeLa cells. Moreover, CHO(DHFR) alpha(v)beta(3)-expressing cells were significantly (P < 0.001) more susceptible to C. pneumoniae infection than CHO(DHFR) cells. These results offer new perspectives on the treatment of C. pneumoniae infection and indicate that alpha(v)beta(3) could be a promising target for new agents developed for activity against this pathogen.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Chlamydophila/tratamento farmacológico , Chlamydophila pneumoniae/efeitos dos fármacos , Pneumopatias/tratamento farmacológico , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 2 da Matriz/uso terapêutico , Animais , Antibacterianos/metabolismo , Antibacterianos/farmacologia , Azitromicina/farmacologia , Azitromicina/uso terapêutico , Células CHO , Infecções por Chlamydophila/microbiologia , Chlamydophila pneumoniae/patogenicidade , Cricetinae , Modelos Animais de Doenças , Células HeLa , Humanos , Integrina alfaV/metabolismo , Integrina beta3/metabolismo , Pneumopatias/microbiologia , Masculino , Metaloproteinase 2 da Matriz/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Resultado do Tratamento
4.
Sichuan Da Xue Xue Bao Yi Xue Ban ; 37(4): 525-9, 2006 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-16909593

RESUMO

OBJECTIVE: To investigate the inhibitory effect of a recombinant adenoviral vector carrying antisense matrix metalloproteinase-2(MMP2) on the growth of hepatocellular carcinoma(HCC) in vivo. METHODS: The recombinant adenoviral vector carrying antisense MMP2(Ad-MMP2(AS))which had been constructed by us in readiness was used to infect the human HCC cell line (Bel-7402). Then the invasiveness of the Bel-7402 cells was assayed in Matrigel, and the production of MMP2 in the Bel-7402 cells was detected with Western blot analysis and Gelatin zymography. After the Ad-MMP2(AS)-infected Bel-7402 cells being subcutaneously inoculated in nude mice, the production of tumors was under observation, and then Ad-MMP2(AS) was injected intratumorally into the pre-existing tumors. RESULTS: Compared with PBS or Ad-CMV-infected cells, infection of Bel-7402 cells with Ad-MMP2(AS) significantly reduced MMP2 enzyme activity, the invasiveness resulted in 52% reduction in Matrigel assays, and the tumor volume displayed a 4.3-fold reduction in nude mice. In addition, direct intratumoral injection of Ad-MMP2(AS) into pre-existing tumors significantly impaired the further expansion of the tumor mass and resulted in a 63% reduction in tumor cell growth. CONCLUSION: The recombinant adenovirus with antisense MMP2 can effectively inhibit the invasiveness and growth of Bel-7402 cells in vitro and in vivo, and has a therapeutic potential for HCC.


Assuntos
Adenoviridae/genética , Neoplasias Hepáticas/patologia , Metaloproteinase 2 da Matriz/biossíntese , Metaloproteinase 2 da Matriz/uso terapêutico , RNA Antissenso/genética , Animais , Carcinoma Hepatocelular/patologia , Linhagem Celular Tumoral , Terapia Genética , Vetores Genéticos , Humanos , Masculino , Metaloproteinase 2 da Matriz/genética , Camundongos , Camundongos Nus , Transplante de Neoplasias , RNA Antissenso/uso terapêutico , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapêutico
6.
Clin Chem Lab Med ; 39(4): 362-7, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11388663

RESUMO

Mediators of extracellular matrix proteins degradation, the matrix metalloproteinases (MMPs), involved in inflammation as well as facilitation of process outgrowth of oligodendrocytes are interesting targets for neural repair. Recent data reported their activation after seizures, cerebral ischemia and spinal cord injury. The present study was designed to localize at cellular level the gelatinase activity by in situ zymography in a rat spinal cord contusion model. The kinetic of gelatinase activation was monitored by in situ zymography on 20 microm cryostat sections. The fluorescein-quenched DQ gelatin digestion yielded cleaved fluorescent peptides enabling the detection of gelatinase activity at cellular level. Twenty four hours and 48 h after injury, a strong gelatinase activity was detected at the lesion site in and around vascular structures and infiltrated cells. A preincubation with either MMP-2 or MMP-9 antibodies significantly decreases the gelatinase activity pattern, suggesting the involvement of at least both MMPs. Our results are consistent with a role for MMPs in the blood spinal barrier disruption, the leukocytes infiltration, the disruption of the extracellular matrix and the clearance of debris.


Assuntos
Metaloproteinases da Matriz/uso terapêutico , Traumatismos da Medula Espinal/tratamento farmacológico , Traumatismos da Medula Espinal/enzimologia , Animais , Contusões/tratamento farmacológico , Matriz Extracelular/metabolismo , Feminino , Gelatinases/metabolismo , Humanos , Imuno-Histoquímica , Hibridização In Situ , Cinética , Leucócitos/metabolismo , Metaloproteinase 2 da Matriz/uso terapêutico , Metaloproteinase 9 da Matriz/uso terapêutico , Neovascularização Patológica , Perfusão , Ratos , Ratos Sprague-Dawley , Medula Espinal/patologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...